186 related articles for article (PubMed ID: 16598622)
1. [Are neurohumoral parameters predictive for the efficacy of cardiac resynchronization therapy? The role of natriuretic peptides].
Sinha AM; Breithardt OA
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I51-5. PubMed ID: 16598622
[TBL] [Abstract][Full Text] [Related]
2. [Natriuretic peptides--new diagnostic markers in heart disease].
Angermann CE; Ertl G
Herz; 2004 Sep; 29(6):609-17. PubMed ID: 15912436
[TBL] [Abstract][Full Text] [Related]
3. [Cardiac resynchronization therapy and arrhythmias].
Böcker D; Gradaus R
Herzschrittmacherther Elektrophysiol; 2005 Mar; 16(1):28-31. PubMed ID: 15824873
[TBL] [Abstract][Full Text] [Related]
4. Echocardiography-based optimization of cardiac resynchronization therapy in patients with congestive heart failure and conduction disorders.
Faber L
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I73-9. PubMed ID: 16598626
[TBL] [Abstract][Full Text] [Related]
5. [Echocardiographic evaluation to select patients for cardiac resynchronization therapy].
Borges AC; Knebel F; Eddicks S; Bondke HJ; Baumann G
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I63-72. PubMed ID: 16598624
[TBL] [Abstract][Full Text] [Related]
6. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
[TBL] [Abstract][Full Text] [Related]
7. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R
Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864
[TBL] [Abstract][Full Text] [Related]
8. [Indication for cardiac resynchronization therapy: Consensus 2005].
Israel CW; Butter C
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I80-6. PubMed ID: 16598627
[TBL] [Abstract][Full Text] [Related]
9. [Is standard-echocardiography sufficient for identification of responders?].
Neuss M; Flach P; Ali T; Butter C
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I56-62. PubMed ID: 16598623
[TBL] [Abstract][Full Text] [Related]
10. [Cardiac resynchronization therapy: are all questions answered?].
Auricchio A
Herzschrittmacherther Elektrophysiol; 2005 Mar; 16(1):1-2. PubMed ID: 15824869
[No Abstract] [Full Text] [Related]
11. Clinical implications of B-type natriuretic peptide and N-terminal pro--B-type natriuretic peptide in the care of the vascular surgery patient.
Wayne Causey M; Singh N
Semin Vasc Surg; 2014 Dec; 27(3-4):143-7. PubMed ID: 26073822
[TBL] [Abstract][Full Text] [Related]
12. [Three-dimensional vectorcardiography to predict CRT-responder].
Koglek W; Brandl J; Oberbichler A; Schmidt K; Grimm G; Butter C
Herzschrittmacherther Elektrophysiol; 2006; 17 Suppl 1():I28-36. PubMed ID: 16598619
[TBL] [Abstract][Full Text] [Related]
13. Role of natriuretic peptides in heart failure patients with special reference to those on cardiac resynchronization therapy.
Ricciardi G; Pieragnoli P; Colella A; Giaccardi M; Padeletti L; Abbate R; Gensini GF; Michelucci A
Minerva Cardioangiol; 2006 Dec; 54(6):743-52. PubMed ID: 17167386
[TBL] [Abstract][Full Text] [Related]
14. [Effect of cardiac resynchronization therapy (CRT) on exercise tolerance, functional capacity and quality of life in patients with congestive heart failure].
Butter C
Herzschrittmacherther Elektrophysiol; 2005 Mar; 16(1):20-7. PubMed ID: 15824872
[TBL] [Abstract][Full Text] [Related]
15. Natriuretic peptides in heart failure and acute coronary syndrome.
Gaggin HK; Januzzi JL
Clin Lab Med; 2014 Mar; 34(1):43-58, vi. PubMed ID: 24507786
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.
Gwechenberger M; Huelsmann M; Graf S; Berger R; Bonderman D; Stanek B; Rauscha F; Pacher R
Eur J Clin Invest; 2004 Dec; 34(12):811-7. PubMed ID: 15606723
[TBL] [Abstract][Full Text] [Related]
17. [Improved identification of suitable patients for cardiac resynchronization therapy by transthoracic echocardiography].
Breithardt OA; Sinha AM
Herzschrittmacherther Elektrophysiol; 2005 Mar; 16(1):10-9. PubMed ID: 15824871
[TBL] [Abstract][Full Text] [Related]
18. Natriuretic Peptides in Clinical Practice.
Çavuşoğlu Y; Alper AT; Altay H; Çelik A; Demirkan B; Güvenç TS; Küçükoğlu MS; Nalbantgil S; Özdemir M; Özin B; Sayın T; Yıldırımtürk Ö; Yılmaz MB; Zorkun C
Anatol J Cardiol; 2019 Mar; 21(Suppl 1):1-40. PubMed ID: 30860204
[TBL] [Abstract][Full Text] [Related]
19. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure.
Gruson D; Ahn SA; Rousseau MF
Peptides; 2015 Feb; 64():24-8. PubMed ID: 25572303
[TBL] [Abstract][Full Text] [Related]
20. [Natriuretic peptides in heart failure].
Emdin M; Poletti R; Giannoni A; Mazzei MG; Mammini C; Gabutti A; Agazio A; Caprioli R; Passino C
G Ital Nefrol; 2006; 23 Suppl 34():S32-7. PubMed ID: 16633992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
